Oral fluoroquinolones are associated with a small but significantly increased risk of acute kidney injury (AKI), Steven T. Bird, PharmD, MS, of the FDA, and colleagues reported online ahead of print in the Canadian Medical Association Journal.

In a study of 1,292 men with AKI and 12,651 matched controls, current use of fluoroquinolones—particularly ciprofloxacin and moxifloxacin—was associated with a twofold increased risk of AKI compared with no use.

n addition, concomitant use of an oral fluoroquinolone and a renin-angiotensin-system blocker increased the risk of acute renal failure by 4.5-fold.

Continue Reading